Dr. John E. Levine, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Eastern Virginia Medical School (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 24
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Eastern Virginia Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
NY license 189751 -
Medical Oncology Physician
NY license 189751
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 24
- Services billed
- 142
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 143 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 31 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Duloxetine Hcl Other prescribers in New York, NY | 15 |
| Gabapentin Other prescribers in New York, NY | 12 |
| Acyclovir Other prescribers in New York, NY | 11 |
| Jakafi (ruxolitinib phosphate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 20 payments worth $31,766 in total to this clinician.
| Mesoblast, Inc. | $11,868 |
|---|---|
| Genzyme Corporation | $9,769 |
| GlaxoSmithKline, LLC. | $3,625 |
| Genetix Biotherapeutics Inc | $3,366 |
| Aimmune Therapeutics, Inc. | $2,719 |
| National Marrow Donor Program | $325 |
| Sanofi-aventis U.S. LLC | $94.70 |
| Consulting Fee | $30,166 |
|---|---|
| Travel and Lodging | $960 |
| Food and Beverage | $640 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mesoblast, Inc. Feb 12, 2025 | Consulting Fee Ryoncil · Steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patie | $11,160 |
| Genzyme Corporation Jun 7, 2025 | Consulting Fee | $9,251 |
| GlaxoSmithKline, LLC. Oct 3, 2025 | Consulting Fee | $2,000 |
| Aimmune Therapeutics, Inc. Jun 26, 2025 | Consulting Fee VOWST · GI | $1,994 |
| GlaxoSmithKline, LLC. Mar 11, 2025 | Consulting Fee | $1,625 |
| Genetix Biotherapeutics Inc Apr 17, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $1,360 |
| Genetix Biotherapeutics Inc Aug 2, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $850 |
| Genetix Biotherapeutics Inc Aug 2, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $850 |
| Aimmune Therapeutics, Inc. Jul 28, 2025 | Consulting Fee VOWST · GI | $725 |
| Mesoblast, Inc. Aug 1, 2025 | Travel and Lodging Ryoncil · Steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patie · travel to Baltimore, MD · in-kind | $708 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genetix Biotherapeutics Inc Nov 17, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $136 |
| GlaxoSmithKline, LLC. Oct 3, 2025 | Consulting Fee | $2,000 |
| Genetix Biotherapeutics Inc Aug 2, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $850 |
| Genetix Biotherapeutics Inc Aug 2, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $850 |
| Mesoblast, Inc. Aug 1, 2025 | Travel and Lodging Ryoncil · Steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patie · travel to Baltimore, MD · in-kind | $708 |
| Aimmune Therapeutics, Inc. Jul 28, 2025 | Consulting Fee VOWST · GI | $725 |
| Aimmune Therapeutics, Inc. Jun 26, 2025 | Consulting Fee VOWST · GI | $1,994 |
| Genzyme Corporation Jun 7, 2025 | Consulting Fee | $9,251 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to Phiadelphia, PA | $252 |
| Genzyme Corporation Jun 7, 2025 | Consulting Fee | $45.00 |
| Genetix Biotherapeutics Inc Apr 17, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $1,360 |
| Genetix Biotherapeutics Inc Apr 17, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $170 |
| GlaxoSmithKline, LLC. Mar 11, 2025 | Consulting Fee | $1,625 |
| Mesoblast, Inc. Feb 12, 2025 | Consulting Fee Ryoncil · Steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patie | $11,160 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $980,947 in research payments for these studies, mostly to the institutions running them.
- A study to evaluate efficacy and safety of GDC 8264 in patients with acute graft versus host disease
Genentech, Inc. - Phase 2 Study Of Ruxolitinib-based Primary Treatment For Acute GVHD
Incyte Corporation - A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic leukemia ALL who are minimal residual disease MRD positive at end of consolidation EOC therapy
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.